Exciting things are happening every day at VCU Massey Cancer Center. We’re saving lives and reducing suffering from cancer. We’re discovering new and better ways to prevent, diagnose and treat cancer. We’re offering opportunities for the community to join us in the progress against cancer.
Updates to outpatient care at Massey due to COVID-19
At VCU Massey Cancer Center we have implemented changes in our clinics to mitigate the coronavirus (COVID-19) situation and keep our patients and medical teams safe.
Thanks to philanthropic leadership, Massey Cancer Centers’ immunotherapy research program received a booster shot of more than $6.6 million to support the cancer center’s immuno-oncology efforts through research, clinical trials and the recruitment and retention of talented physician-scientists working to advance treatment options.
Jose G. Trevino, M.D., FACS, has been appointed chair of the Division of Surgical Oncology at the VCU School of Medicine and surgeon in chief at VCU Massey Cancer Center. He will also hold the Walter Lawrence, Jr., Distinguished Professor of Oncology at Massey and will be an associate professor in the Division. He will join VCU on November 1, 2020.
Last year, 12 patients in the Supportive Care Clinic at VCU Massey Cancer Center stepped inside a conference room, donned motion sensors and engaged in a facilitated life review, acting out various parts of their lives through a virtual avatar displayed on a projection screen. Recently, the unique collaboration between researchers at VCUarts and Massey’s Palliative Care Program was recognized with a tie for first place in the 2nd Annual Hamilton International Arts in Health Awards from the National Organization for Arts in Health (NOAH).
Today, the U.S. Preventive Services Task Force released a draft recommendation that colorectal cancer screening should begin at age 45. The recommendation to screen applies to all adults 45-75 years old without symptoms, a personal history of colorectal polyps or a personal or family history of genetic disorders that increase the risk of colorectal cancer.
Massey scientist awarded $1.7M to identify drugs that can overcome chemotherapy resistance and effectively treat advanced breast cancer
Triple-negative breast cancer (TNBC) is an aggressive form of disease that makes up about 10-15% of all breast cancers, according to the American Cancer Society. Because these tumors grow faster, and there are limited treatment options, patient outcomes are worse compared to other types of breast cancer. Chuck Harrell, Ph.D., member of the Cancer Molecular Genetics research program at VCU Massey Cancer Center, was recently awarded a $1.7 million R01 grant from the National Cancer Institute to identify targeted drugs that can overcome chemotherapy resistance and effectively treat TNBC.